Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists - Scorecard - MDSpire
Advertisement
Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists
Clinical Scorecard: Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists
At a Glance
Category
Detail
Condition
Key Mechanisms
5-ASA is used for its favorable safety profile and perceived efficacy in mild cases, despite lack of evidence.
Target Population
Care Setting
Key Highlights
90.4% of physicians prescribe 5-ASA for Crohn's disease.
Primarily used for mild disease and colonic involvement.
Majority of prescriptions are in combination with corticosteroids.
International guidelines do not recommend 5-ASA for Crohn's disease.
Significant evidence-practice gap exists among Chinese clinicians, with X% of physicians acknowledging the lack of evidence.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Therapeutic inertia may delay the initiation of more effective therapies.
Educate clinicians on the risks associated with therapeutic inertia.
Patient & Prescribing Data
Patients with mild, non-stricturing, non-penetrating Crohn's disease.
5-ASA is perceived as effective by a majority of prescribing physicians despite lack of evidence.
Clinical Best Practices
Educate clinicians on the evidence against 5-ASA use in Crohn's disease.
Encourage adherence to international guidelines for Crohn's disease management through workshops and seminars.
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
